Functional and motor response to low dose olanzapine in Huntington's disease: case report.
Previous reports on the use of olanzapine in Huntington's disease (HD) used doses ranging from 10-30 mg. We report a case of HD with marked delusions and behavioral impairment assessed by the Unified Huntington's Disease Rating Scale at baseline and four months later treated with a low dose of olanzapine. The patient improved in motor, psychiatric and activity of daily living symptoms after four months of treatment. The response to a low dose of olanzapine in HD may be an indicator of efficacy in similar cases. Further randomized controlled trials can properly assess these findings.
Laks
Jerson
J
Center for Alzheimer's Disease and Related Disorders, Psychiatry Institute, Federal University of Rio de Janeiro, Brazil. jlaks@centroin.com.br
Rocha
Marlos
M
Capitão
Claudia
C
Domingues
Romeu Côrtes
RC
Ladeia
Giovanna
G
Lima
Maurício
M
Engelhardt
Eliasz
E
D014150:Antipsychotic Agents / Q000008:administration & dosage*; D001569:Benzodiazepines / Q000008:administration & dosage; D003071:Cognition / Q000187:drug effects; D005260:Female; D006801:Humans; D006816:Huntington Disease / Q000188:drug therapy*; D008875:Middle Aged; D009043:Motor Activity / Q000187:drug effects; D000077152:Olanzapine
D014150:Antipsychotic Agents; D001569:Benzodiazepines; D000077152:Olanzapine